Skip to main content

Advertisement

SpringerLink
Log in

Management of Chronic Lymphocytic Leukaemia

  • Disease Management
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in Western countries. The diagnosis requires mature-appearing lymphocytes in the peripheral blood to >5 × 109/L. The immunophenotype typically includes B cell antigens CD19, CD20 and CD23, low expression of surface immunoglobulin and CD5+, with other T cell antigens absent. Bone marrow biopsy, although not required for diagnosis, must show at least 30% lymphocytes. Cytogenetic abnormalities are frequent in patients with CLL, and may be associated with poor prognosis.

Clinically, most patients are asymptomatic at presentation, with incidental lymphadenopathy and/or hepatosplenomegaly in the routine physical examination. Infections by opportunistic pathogens are the major cause of death. Aggressive transformation occurs in 10% of patients with CLL, most commonly prolymphocytic leukaemia (PLL) and Richter’s syndrome. PLL de novo must be differentiated from PLL of an aggressive transformation. The incidences of autoimmune diseases and solid or haemopoietic secondary malignancies are increased in patients with CLL.

Clinical stage is the strongest prognostic factor in CLL. There is no indication for early intervention. The current recommendation to start treatment includes disease-related symptoms, massive and/or progressive hepatosplenomegaly or lymphadenopathy, increasing bone marrow failure, autoimmune disease, and recurrent infections.

Alkylating agents (e.g. chlorambucil) and nucleoside analogues (e.g. fludarabine) are the most active agents for CLL. Fludarabine induces higher response rates, but no improvement in overall survival has been observed. Fludarabine is the drug of choice for the majority of patients with CLL. Chlorambucil may be helpful for elderly patients with poor performance, and for patients who do not tolerate fludarabine. No drug combination is better than single agents.

For patients refractory to initial treatment, referral to a clinical trial is the best choice. Other salvage therapy includes retreatment with the same initial agent (chlorambucil or fludarabine) if initial response was observed, or fludarabine for patients refractory to chlorambucil.

Promising new approaches include cycle-active agents, nelarabine, biological therapy such as anti-CD52 monoclonal antibody, bone marrow transplantation, including the use of submyeloablative preparative regimens (‘minitransplant’) to induce graft-versus-leukaemia effect, and gene therapy.

Prophylactic antibacterials and intravenous immunoglobulin should not be used routinely during supportive care. Epoetin may be helpful for patients who have anaemia without obvious cause.

Assessment of response to therapy in CLL has been updated by the National Cancer Institute Working Group, and these guidelines are used worldwide for clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1998; 48(1): 6–29

    Article  PubMed  CAS  Google Scholar 

  2. Ries LAG, Miller BA, Hankey BF, et al., editors. Surveillance Epidemiology End Results (SEER) Cancer Statistics Review, 1973–1991: tables and graphs. Bethesda (MD): National Cancer Institute; 1994. Report no.: NIH-94-2789

    Google Scholar 

  3. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: report of the NCI-sponsored Working Group. Am J Hematol 1988; 29: 152–63

    Article  PubMed  CAS  Google Scholar 

  4. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–7

    PubMed  CAS  Google Scholar 

  5. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–92

    PubMed  CAS  Google Scholar 

  6. Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol 1989; 42: 567–84

    Article  PubMed  CAS  Google Scholar 

  7. Heath ME, Cheson BD. Defective complement activity in chronic lymphocytic leukemia. Am J Hematol 1985; 19: 63–73

    Article  PubMed  CAS  Google Scholar 

  8. Morrison VA. The infectious complications of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 98–106

    PubMed  CAS  Google Scholar 

  9. Robertson LE, Pugh W, O’Brien S, et al. Richter’s syndrome: a report on 39 patients. J Clin Oncol 1993; 11: 1985–9

    PubMed  CAS  Google Scholar 

  10. Melo JV, Wardle J, Chetty M, et al. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia III: evaluation of cell size by morphology and volume measurements. Br J Haematol 1986; 64: 469–78

    Article  PubMed  CAS  Google Scholar 

  11. Melo JV, Catovsky D, Galton DAG. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia: I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986; 63: 377–87

    Article  PubMed  CAS  Google Scholar 

  12. Melo JV, Catovsky D, Galton DAG. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia: II. Patterns of evolution of ‘prolymphocytoid’ transformation. Br J Haematol 1986; 64: 77–86

    Article  PubMed  CAS  Google Scholar 

  13. Melo JV, Catovsky D, Gregory WM, et al. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia: IV Analysis of survival and prognostic features. Br J Haematol 1987; 65(1): 23–9

    Article  PubMed  CAS  Google Scholar 

  14. Fitzgerald PH, Rastrick JM, Hamer JW. Acute plasma cell leukaemia following chronic lymphatic leukaemia: transformation or two separate diseases? Br J Haematol 1973; 25: 171–7

    Article  PubMed  CAS  Google Scholar 

  15. Brecher M, Banks PM. Hodgkin’s disease variant of Richter’s syndrome: report of eight cases. Am J Clin Pathol 1989; 93: 333–9

    Google Scholar 

  16. Hamblin TJ, Oscier DJ, Young BJ. Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 1986; 39(7): 713–6

    Article  PubMed  CAS  Google Scholar 

  17. Duhrsen U, Augener W, Zwingers T, et al. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67: 235–9

    Article  PubMed  CAS  Google Scholar 

  18. Ritch PS, Anderson T. Reversal of autoimmune hemolytic anemia associated with chronic lymphocytic leukemia following high-dose immunoglobulin. Cancer 1987; 60: 2637–40

    Article  PubMed  CAS  Google Scholar 

  19. Majer RV, Hyde RD. High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia. Clin Lab Haematol 1988; 10: 391–5

    PubMed  CAS  Google Scholar 

  20. Seymour JF, Cusack JD, Lerner SA, et al. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 52–60

    PubMed  CAS  Google Scholar 

  21. Abeloff MD, Waterbury L. Pure red blood cell aplasia and chronic lymphocytic leukemia. Arch Intern Med 1974; 134: 721–4

    Article  PubMed  CAS  Google Scholar 

  22. Mangan KF, Chikkappa G, Farley PC. T gamma (Tγ) cells suppress growth of erythroid colony-forming units in vitro in the pure red cell aplasia of B-cell chronic lymphocytic leukemia. J Clin Invest 1982; 70: 1148–56

    Article  PubMed  CAS  Google Scholar 

  23. Vashi P, Patel B, Musson P, et al. Corticosteroid-responsive pure red cell aplasia in chronic lymphatic leukemia. Am J Hematol 1987; 26: 279–84

    Article  PubMed  CAS  Google Scholar 

  24. Chikkappa G, Pasquale D, Zarrabi MH, et al. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am J Hematol 1992; 41: 5–12

    Article  PubMed  CAS  Google Scholar 

  25. Chikkappa G, Pasquale D, Phillips PG, et al. Cyclosporine-A for the treatment of pure red cell aplasia in a patients with chronic lymphocytic leukemia. Am J Hematol 1987; 26: 179–89

    Article  PubMed  CAS  Google Scholar 

  26. Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232: 267–9

    Article  PubMed  CAS  Google Scholar 

  27. Greene MH, Hoover RN, Fraumeni Jr JF. Subsequent cancer in patients with chronic lymphocytic leukemia: a possible immunologic mechanism. J Natl Cancer Inst 1978; 61: 337–40

    PubMed  CAS  Google Scholar 

  28. van Scoy-Mosher MB, Bick M, Capostagno V, et al. A clinicopathologic analysis of chronic lymphocytic leukemia. Am J Hematol 1981; 10: 9–18

    Article  PubMed  Google Scholar 

  29. Gabrail NY, Martin TW. Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. Acta Haematol 1991; 85: 31–3

    Article  PubMed  CAS  Google Scholar 

  30. Travis LB, Curtis RE, Hankey BF, et al. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84: 1422–7

    Article  PubMed  CAS  Google Scholar 

  31. Davis JW, Weiss NS, Armstrong BK. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1987; 78: 91–4

    PubMed  CAS  Google Scholar 

  32. Molica S, Alberti A. Second neoplasms in chronic lymphocytic leukemia: analysis of incidence as a function of the length of follow-up. Haematologica 1989; 74: 481–5

    PubMed  CAS  Google Scholar 

  33. Stern N, Shemesh J, Ramot B. Chronic lymphatic leukemia terminating in acute myeloid leukemia: review of the literature. Cancer 1981; 47: 1849–51

    Article  PubMed  CAS  Google Scholar 

  34. Choi H, Keller RH. Coexistence of chronic lymphocytic leukemia and Hodgkin’s disease. Cancer 1981; 48: 48–57

    Article  PubMed  CAS  Google Scholar 

  35. Schreiber ZA, Axelrod MR, Abebe LS. Coexistence of chronic myelogenous leukemia and chronic lymphocytic leukemia. Cancer 1984; 54: 697–701

    Article  PubMed  CAS  Google Scholar 

  36. Eridani S, Parry H, Glass U, et al. Acute lymphoblastic leukemia supervening in a case of chronic lymphocytic leukemia after continuous 3-year treatment with chlorambucil. Cancer 1984; 54: 397–9

    Article  PubMed  CAS  Google Scholar 

  37. Duchayne E, Delsol G, Kuhlein E, et al. Hairy cell transformation of a B-cell chronic lymphocytic leukemia: a morphological, cytochemical, phenotypic and molecular study. Leukemia 1991; 5: 150–5

    PubMed  CAS  Google Scholar 

  38. Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival: a report from the MRC CLL 1 trial. Br J Haematol 1989; 72: 141–9

    Article  PubMed  CAS  Google Scholar 

  39. French Cooperative Group on Chronic Lymphocytic Leukemia F. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized trial on 612 patients. Blood 1990; 75: 1414–21

    Google Scholar 

  40. Zwiebel J, Cheson BD. Prognostic factors in chronic lymphocytic leukemia. Semin Oncol 1998; 25: 42–59

    PubMed  CAS  Google Scholar 

  41. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–34

    PubMed  CAS  Google Scholar 

  42. Cheson BD. Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation. Semin Hematol 1998; 35: 14–21

    PubMed  CAS  Google Scholar 

  43. Rai KR, Montserrat E. Prognostic factors in chronic lymphocytic leukemia. Semin Hematol 1987; 24(4): 252–6

    PubMed  CAS  Google Scholar 

  44. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206

    Article  PubMed  CAS  Google Scholar 

  45. Mandelli F, De Rossi G, Mancini P, et al. Prognosis in chronic lymphocytic leukemia: a retrospective multicentric study from the GIMEMA group. J Clin Oncol 1987; 5: 398–406

    PubMed  CAS  Google Scholar 

  46. French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76: 45–57

    Article  Google Scholar 

  47. Lee JS, Dixon DO, Kantarjian HM, et al. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987; 69: 929–36

    PubMed  CAS  Google Scholar 

  48. Pines A, Ben-Bassat I, Modan M, et al. Survival and prognostic factors in chronic lymphocytic leukemia. Eur J Haematol 1987; 38: 123–30

    Article  PubMed  CAS  Google Scholar 

  49. Rozman C, Montserrat E, Rodríguez-Fernández JM, et al. Bone marrow histologic pattern: the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–8

    PubMed  CAS  Google Scholar 

  50. Keating MJ, Lerner S, Kantarjian H, et al. The serum β2-microglobulin (β2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) [abstract]. Blood 1995; 86: 606

    Google Scholar 

  51. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259–64

    PubMed  CAS  Google Scholar 

  52. Hamblin TJ, Davis Z, Oscier DG, et al. In chronic lymphocytic leukemias germline configuration of immunoglobulin heavy chain genes is associated with a more aggressive form of the disease [abstract]. Blood 1998; 92: 515a

    Google Scholar 

  53. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999; 93: 1732–7

    PubMed  CAS  Google Scholar 

  54. Stilgenbauer S, Döhner K, Bentz M, et al. Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia. Ann Hematol 1998; 76: 101–10

    Article  PubMed  CAS  Google Scholar 

  55. Döhner H, Stilgenbauer S, Döhner K, et al. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999; 77: 266–81

    Article  PubMed  Google Scholar 

  56. Montserrat E, Viñolas N, Reverer JC, et al. Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early stages. Nouv Rev Fr Hematol 1988; 30: 359–61

    PubMed  CAS  Google Scholar 

  57. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia: French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506–14

    Article  PubMed  CAS  Google Scholar 

  58. Shustik C, Mick R, Silver R, et al. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 1988; 6: 7–12

    Article  PubMed  CAS  Google Scholar 

  59. Richards S, Clarke M. Meta-analysis of results: CLL Trialists’ Cooperative Group. Hematol Cell Ther 1997; 39: S53–102

    Article  Google Scholar 

  60. Montserrat E, Sanchez-Bisono J, Viñolas N, et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–75

    Article  PubMed  CAS  Google Scholar 

  61. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712–6

    Article  PubMed  CAS  Google Scholar 

  62. Tura S, Cavo M, Galieni P, et al. Staging classification of chronic lymphocytic leukemia. Recenti Prog Med 1986; 77(2): 100–3

    PubMed  CAS  Google Scholar 

  63. Montserrat E, Gomis F, Vallespí T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 1991; 78: 1545–51

    PubMed  CAS  Google Scholar 

  64. Cheson BD. New antimetabolites in the treatment of human malignancies. Semin Oncol 1992; 19: 695–706

    PubMed  CAS  Google Scholar 

  65. Keating MJ, O’Brian S, Kantarjian H, et al. Nucleoside analogs in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 1993; 10 Suppl.: 139–45

    Article  PubMed  Google Scholar 

  66. Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991; 5: 133–8

    Article  Google Scholar 

  67. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 433–8

    PubMed  CAS  Google Scholar 

  68. Sorensen JM, Vena D, Fallavollita A, et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C mechanism of the National Cancer Institute: 5-year follow-up report. J Clin Oncol 1997; 15: 458–65

    PubMed  CAS  Google Scholar 

  69. Sawitsky A, Rai KR, Glidewell O, et al. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049–59

    PubMed  CAS  Google Scholar 

  70. Han T, Ezdinli EZ, Shimaoka K, et al. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973; 31: 502–8

    Article  PubMed  CAS  Google Scholar 

  71. Spanish Cooperative Group P. Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (PETHEMA) trials. Leuk Lymphoma 1991; 5: 89–91

    Article  Google Scholar 

  72. Rai KR, Peterson B, Elias L, et al. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: a CALGB, SWOG, CTC/NCI-C and ECOG inter-group study [abstract]. Blood 1996; 88: 141a

    Google Scholar 

  73. Liepman M, Votaw ML. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 1978; 41: 1664–9

    Article  PubMed  CAS  Google Scholar 

  74. Montserrat E, Alcala A, Parody R, et al. Treatment of chronic lymphocytic leukemia in advanced stages: a randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985; 56: 2369–75

    Article  PubMed  CAS  Google Scholar 

  75. Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991; 9: 770–6

    PubMed  CAS  Google Scholar 

  76. French Cooperative Group on Chronic Lymphocytic Leukemia: long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. Br J Haematol 1989; 73: 334–40

    Google Scholar 

  77. Hansen MM, Andersen E, Birgens H, et al. CHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia: preliminary results of a randomized multicenter study. Nouv Rev Fr Hematol 1998; 30(5-6): 433–6

    Google Scholar 

  78. Kimby E, Millstedt H. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type: a randomized trial. Leuk Lymphoma 1991; 5: 93–6

    Article  Google Scholar 

  79. Keating MJ, Scouros M, Murphy S, et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157–64

    PubMed  CAS  Google Scholar 

  80. Keating MJ, Hester JP, McCredie KB, et al. Long-term results of CAP therapy in chronic lymphocytic leukemia. Leuk Lymphoma 1990; 2: 391–7

    Article  Google Scholar 

  81. Johnson S, Smith AG, French Cooperative Group on CLL, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996; 347: 1432–8

    PubMed  CAS  Google Scholar 

  82. French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 1990; 75: 1422–5

    Google Scholar 

  83. Montserrat E, Alcala A, Alonso C, et al. A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. Nouv Rev Fr Hematol 1988; 30: 429–32

    PubMed  CAS  Google Scholar 

  84. Kempin S, Lee III BJ, Thaler HT, et al. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood 1982; 60: 1110–21

    PubMed  CAS  Google Scholar 

  85. Case Jr DC, Porensky RS, Fanning JP. Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV). Oncology 1985; 42: 350–3

    Article  PubMed  Google Scholar 

  86. Smith GM, Child JA, Milligan DW, et al. A pilot study of epirubicin and chlorambucil in the treatment of chronic lymphocytic leukemia (CLL). Hematol Oncol 1991; 9: 315–21

    Article  PubMed  CAS  Google Scholar 

  87. Leporrier M, Chevret S, Cazin B, et al. Randomised comparison of fludarabine, CAP and CHOP in 695 previously untreated stage B and C CLL [abstract]. Hematol Cell Ther 1997; 39: S58–9

    Google Scholar 

  88. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457–9

    PubMed  CAS  Google Scholar 

  89. Keating MJ, O’Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–84

    PubMed  CAS  Google Scholar 

  90. O’Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–700

    PubMed  Google Scholar 

  91. Whelan JS, Davis CL, Rule S, et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 1991; 64: 120–3

    Article  PubMed  CAS  Google Scholar 

  92. Hiddemann W, Rottmann R, Wormann B, et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine: results of a clinical phase-II study. Ann Hematol 1991; 63: 1–4

    Article  PubMed  CAS  Google Scholar 

  93. Montserrat E, López-Lorenzo JL, Manso F, et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk Lymphoma 1996; 21: 467–72

    Article  PubMed  CAS  Google Scholar 

  94. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease in blood lymphocyte count. J Clin Oncol 1993; 11: 679–89

    PubMed  CAS  Google Scholar 

  95. Tallman MS, Hakimian D, Zonzig C, et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 983–8

    PubMed  CAS  Google Scholar 

  96. Delannoy A, Martiat P, Gala JL, et al. 2-Chlorodeoxyadenosine (Cd A) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130–5

    PubMed  CAS  Google Scholar 

  97. Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570–4

    PubMed  CAS  Google Scholar 

  98. Robak T, Blasinka-Morawiec M, Krykowski E, et al. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1996; 22: 509–14

    Article  PubMed  CAS  Google Scholar 

  99. Rondelli D, Lauria F, Zinzani PL, et al. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haematol 1997; 58: 46–50

    Article  PubMed  CAS  Google Scholar 

  100. Robak T, Blonski JZ, Urbanska-Rys H, et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999; 13: 518–23

    Article  PubMed  CAS  Google Scholar 

  101. Robak T, Blasinska-Morawiec M, Blonski JZ, et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1999; 34: 151–7

    PubMed  CAS  Google Scholar 

  102. Grever MR, Leiby JM, Kraut EH, et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985; 3: 1196–201

    PubMed  CAS  Google Scholar 

  103. O’Dwyer PJ, Wagner B, Leyland-Jones B, et al. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Ann Intern Med 1988; 108: 733–43

    PubMed  Google Scholar 

  104. Ho AD, Thaler J, Strykmans P, et al. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1990; 82: 1416–20

    Article  PubMed  CAS  Google Scholar 

  105. Dearden C, Catovsky D. Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 1990; 62: 4–5

    Article  PubMed  CAS  Google Scholar 

  106. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–71

    PubMed  CAS  Google Scholar 

  107. Robertson LE, O’Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 1444–9

    PubMed  CAS  Google Scholar 

  108. Cheson BD, Vena D, Foss F, et al. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12: 2216–28

    PubMed  CAS  Google Scholar 

  109. Cheson BD. Immunologic and immunosuppressive complications of purine analogue therapy. J Clin Oncol 1995; 13: 2431–48

    PubMed  CAS  Google Scholar 

  110. Anaissie E, Kontoyiannis DP, Kantarjian H, et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1992; 117: 466–9

    PubMed  CAS  Google Scholar 

  111. Anaissie EJ, Kontoyiannis DP, O’Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559–66

    PubMed  CAS  Google Scholar 

  112. Cheson BD, Frame JN, Vena D, et al. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 2313–20

    PubMed  CAS  Google Scholar 

  113. List AF, Kummet TD, Adams JD, et al. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 1990; 89: 388–90

    Article  PubMed  CAS  Google Scholar 

  114. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175–88

    PubMed  CAS  Google Scholar 

  115. Cervantes F, Slagado C, Montserrat E, et al. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis. Lancet 1990; 336: 1130–1

    Article  PubMed  CAS  Google Scholar 

  116. Cohen RB, Abdallah JM, Gray JR, et al. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 1993; 118: 114–6

    PubMed  CAS  Google Scholar 

  117. Schilling PJ, Vadhan-Raj S. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia [letter]. N Engl J Med 1990; 323: 833–4

    Article  PubMed  CAS  Google Scholar 

  118. Chun HG, Leyland-Jones BR, Caryk SM, et al. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986; 70: 1225–8

    PubMed  CAS  Google Scholar 

  119. Hurst PG, Habib M, Garewal H, et al. Pulmonary toxicity associated with fludarabine monophosphate. Invest New Drugs 1987; 5: 207–10

    Article  PubMed  CAS  Google Scholar 

  120. Spriggs DR, Stopa E, Mayer RJ, et al. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 1986; 46: 5953–8

    PubMed  CAS  Google Scholar 

  121. Casper ES, Mittelman A, Kelson D, et al. Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 1985; 15: 233–5

    Article  PubMed  CAS  Google Scholar 

  122. Warrell Jr RP, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4: 74–9

    PubMed  Google Scholar 

  123. Elias L, Stock-Novak D, Grever M, et al. A phase I trial of combination fludarabine and chlorambucil in chronic lymphocytic leukemia [abstract]. Proc Am Soc Clin Oncol 1991; 10: 221

    Google Scholar 

  124. Bastion Y, Coiffier B, Dumontet C, et al. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992; 3: 171–2

    PubMed  CAS  Google Scholar 

  125. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341–4

    Article  PubMed  CAS  Google Scholar 

  126. Tertian G, Cartron J, Bayle C, et al. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38: 359–60

    Article  PubMed  CAS  Google Scholar 

  127. Longo G. Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia. Eur J Haematol 1997; 59: 124–5

    Article  PubMed  CAS  Google Scholar 

  128. Tsiara S, Christou L, Konstantinidou P, et al. Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia. Am J Hematol 1997; 54(4): 342

    Article  PubMed  CAS  Google Scholar 

  129. Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 1885–9

    PubMed  CAS  Google Scholar 

  130. Cheson BD, Vena D, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy of chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454–60

    PubMed  CAS  Google Scholar 

  131. Puccio CA, Mittelman A, Lichtman SM, et al. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 1562–9

    PubMed  CAS  Google Scholar 

  132. Robertson LE, O’Brien S, Koller C, et al. Athree-day schedule of fludarabine in chronic lymphocytic leukemia (CLL) [abstract]. Blood 1992; 80: 47a

    Google Scholar 

  133. Kemena A, O’Brien S, Kantarjian H, et al. A phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 1993; 10: 187–93

    Article  PubMed  CAS  Google Scholar 

  134. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate. J Clin Oncol 1999; 17: 1574–9

    PubMed  CAS  Google Scholar 

  135. Lilliemark JO, Albertioni F, Pettersson B, et al. Bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine (CdA) [abstract]. Proc Am Soc Clin Oncol 1992; 11: 112

    Google Scholar 

  136. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160–6

    PubMed  CAS  Google Scholar 

  137. Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–21

    Article  PubMed  CAS  Google Scholar 

  138. Saven A, Kawasaki H, Carrera CJ, et al. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 1993; 11: 671–8

    PubMed  CAS  Google Scholar 

  139. Spielberger RT, Stock W, Larson RA. Listeriosis after 2-chlorodeoxyadenosine treatment [letter]. N Engl J Med 1993; 328: 813–4

    Article  PubMed  CAS  Google Scholar 

  140. Kefford RF, Fox RM. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes. Br J Haematol 1982; 50: 627–36

    Article  PubMed  CAS  Google Scholar 

  141. Grever MR, Siaw MFE, Jacob WF, et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406–17

    PubMed  CAS  Google Scholar 

  142. Ho AD, Ganeshaguru K, Knauf WU, et al. Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo. Blood 1988; 72: 1884–90

    PubMed  CAS  Google Scholar 

  143. Grever MR, Leiby JM, Kraut EH, et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985: 3(9): 1196–201

    PubMed  CAS  Google Scholar 

  144. O’Dwyer PJ, Spiers ASD, Marsoni S. Association of severe and fatal infections and treatment with pentostatin. Cancer Treat Rep 1986; 70: 1117–20

    PubMed  Google Scholar 

  145. Daeninck PJ, Johnston JB, Eisenhauer E, et al. Treatment of hairy cell leukemia with low-dose 2′-deoxycoformycin: results of long-term follow-up [abstract no. 60]. Proc Am Soc Clin Oncol 1997; 16: 17a

    Google Scholar 

  146. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term results in hairy cell leukemia (HCL) treated with pentostatin [abstract]. Blood 1997; 90: 578a

    Google Scholar 

  147. Oken MM, Kaplan ME. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia. Cancer Treat Rep 1979; 63: 441–7

    PubMed  CAS  Google Scholar 

  148. Velasquez WS, McLaughlin P, Swan F, et al. Dexamethasone, high dose ara-C and cisplatin (DHAP) combination for progressive chronic lymphocytic leukemia [abstract]. Blood 1986; 68: 234a

    Google Scholar 

  149. McCroskey RD, Mosher DF, Spencer CD, et al. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer 1990; 66: 246–50

    Article  PubMed  CAS  Google Scholar 

  150. De Rossi G, Mauro FR, Pizzo F, et al. Combination of cytosinearabinoside (ARA-C), cyclophosphamide and prednisone in the treatment of B-chronic lymphocytic leukemia in advanced stages and progressive disease. Leuk Lymphoma 1991; 5: 101–3

    Article  Google Scholar 

  151. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25

    PubMed  CAS  Google Scholar 

  152. Weiss M, Kempin S, Berman E, et al. Results of a phase I study of fludarabine phosphate (FAMP) plus chlorambucil (CLB) in patients with chronic lymphocytic leukemia [abstract no. 914]. Proc Am Soc Clin Oncol 1992; 11: 276

    Google Scholar 

  153. Gandhi V, Nowak B, Keating MJ, et al. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 1989; 74: 2070–5

    PubMed  CAS  Google Scholar 

  154. Gandhi V, Kemena A, Keating MJ, et al. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 1992; 52: 897–903

    PubMed  CAS  Google Scholar 

  155. O’Brien S, Kantarjian H, Koller C, et al. Fludarabine-prednisone: a highly effective regimen in chronic lymphocytic leukemia (CLL) [abstract no. 850]. Proc Am Soc Clin Oncol 1992; 11: 260

    Google Scholar 

  156. Foss F, Ihde D, Phelps R, et al. Phase II study of fludarabine and interferon-alfa-2A in advanced mycosis fungoides/Sezary syndrome (MF/SS) [abstract no. 1068]. Proc Am Soc Clin Oncol 1992; 11: 315

    Google Scholar 

  157. O’Brien S, Kantarjian H, Beran M, et al. Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL) [abstract]. Int J Hematol 1996; 64: S56

    Google Scholar 

  158. Rummel M, Schenk M, Renner C, et al. Fludarabine and epirubicin in the treatment of CLL as first line therapy or in first relapse: results of a phase-II-study [abstract]. Blood 1997; 90: 530a

    Google Scholar 

  159. Bosch F, Perales M, Cobo F, et al. Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) [abstract]. Blood 1997; 90: 530a

    Google Scholar 

  160. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chloro-2′-deoxyadenosine (CDA) in B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056–61

    Article  PubMed  CAS  Google Scholar 

  161. Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine [letter]. N Engl J Med 1993; 328: 812–3

    Article  PubMed  CAS  Google Scholar 

  162. Delannoy A, Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine [letter]. N Engl J Med 1993; 328: 812

    Article  PubMed  CAS  Google Scholar 

  163. Rai KR, Sawitsky A, Janson D, et al. Salvage therapy with 2-chlorodeoxyadenosine (2-CdA) in advanced B-chronic lymphocytic leukemia (CLL) is effective in patients (PTS) without prior fludarabine (F) exposure [abstract no. 1034]. Proc Am Soc Clin Oncol 1994; 13: 314

    Google Scholar 

  164. O’Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330: 319–22

    Article  PubMed  Google Scholar 

  165. O’Brien S, Kantarjian H, Ellis A, et al. Topotecan in chronic lymphocytic leukemia. Cancer 1995; 75: 1104–108

    Article  PubMed  Google Scholar 

  166. Al-Katib A, Mohammed RM, Dan M, et al. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol 1993; 21: 61–5

    PubMed  CAS  Google Scholar 

  167. Varterasian ML, Mohammad RM, Eilender DS, et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 56–62

    PubMed  CAS  Google Scholar 

  168. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804–16

    PubMed  CAS  Google Scholar 

  169. Al-Katib A, Wang CY, McKenzie S, et al. Phorbol ester-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Am J Hematol 1992; 40: 264–9

    Article  PubMed  CAS  Google Scholar 

  170. Kurtzberg J, Keating MJ, Plunkett W, et al. Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: preliminary results of an ongoing phase I trial [abstract]. J Clin Oncol 1996; 14: 1750

    Google Scholar 

  171. Gandhi V, Plunkett W, Rodriguez Jr C, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 1998; 16(11): 3607–15

    PubMed  CAS  Google Scholar 

  172. Foon KA, Bottino GC, Abrams PG, et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 1985; 78: 216–20

    Article  PubMed  CAS  Google Scholar 

  173. Schulof RS, Lloyd MJ, Stallings JJ, et al. Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity. J Biol Response Mod 1985; 4: 310–23

    PubMed  CAS  Google Scholar 

  174. O’Connell MJ, Colgan JP, Oken MM, et al. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukemia: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1986; 4: 128–36

    PubMed  Google Scholar 

  175. Boussiotis VA, Pangalis GA. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up. Br J Haematol 1991; 79: 30–3

    Article  PubMed  Google Scholar 

  176. Rozman C, Montserrat E, Viñolas N, et al. Recombinant α2-interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood 1988; 71: 1295–8

    PubMed  CAS  Google Scholar 

  177. Ziegler-Heitbrock HWL, Schlag R, Flieger D, et al. Favorable response of early stage B CLL patients to treatment with IFN-α2. Blood 1989; 73: 1426–30

    PubMed  CAS  Google Scholar 

  178. Molica S, Alberti A. Recombinant alpha-2a interferon in treatment of B-chronic lymphocytic leukemia: a preliminary report with emphasis on previously untreated patients in early stage of disease. Haematologica 1990; 75: 75–8

    PubMed  CAS  Google Scholar 

  179. Ferrara F, Rametta V, Mele G, et al. Recombinant interferon-alpha-2A as maintenance treatment for patients with advanced stage chronic lymphocytic leukemia responding to chemotherapy. Am J Hematol 1992; 41: 45–9

    Article  PubMed  CAS  Google Scholar 

  180. O’Brien S, Kantarjian H, Beran M, et al. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine. Blood 1995; 86: 1296–300

    Google Scholar 

  181. Zinzani PL, Bendandi M, Magagnoli M, et al. Results with fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin’s lymphoma. Eur J Haematol 1997; 59: 82–8

    Article  PubMed  CAS  Google Scholar 

  182. Grossbard ML, Freedman AS, Ritz J, et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992; 79: 576–85

    PubMed  CAS  Google Scholar 

  183. Dillman RO, Shawler DL, Dillman JB, et al. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2: 881–91

    PubMed  CAS  Google Scholar 

  184. Hertler AA, Schlossman DM, Borowitz MJ, et al. A phase I study of T101 -ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Response Mod 1988; 7: 97–113

    PubMed  CAS  Google Scholar 

  185. DeNardo GJ, Lewis JP, DeNardo SJ, et al. Effect of lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 1993; 73: 1425–32

    Article  Google Scholar 

  186. Capel PJA, Preijers FWMB, Allebes WA, et al. Treatment of chronic lymphocytic leukaemia with monoclonal anti-idiotype antibody. Neth J Med 1985; 28: 112–8

    PubMed  CAS  Google Scholar 

  187. Dyer MJS, Hale G, Hayhoe FGJ, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431–9

    PubMed  CAS  Google Scholar 

  188. Pawson R, Dyer MJS, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667–72

    PubMed  CAS  Google Scholar 

  189. Österborg A, Dyer MJS, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–74

    PubMed  Google Scholar 

  190. Rawstron AC, Davies FE, Evans P, et al. CAMPATH-1H therapy for patients with refractory chronic lymphocytic leukemia (CLL) [abstract]. Blood 1997; 90: 529a

    Google Scholar 

  191. Bowen AL, Zomas A, Emmett E, et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997; 96: 617–9

    Article  PubMed  CAS  Google Scholar 

  192. Mellstedt H, Österborg A, Lundin J, et al. CAMPATH- 1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL) [abstract]. Blood 1998; 92: 490a

    Google Scholar 

  193. Piro L, White CA, Grillo-López AJ, et al. RITUXAN™ (rituximab, IDEC-C2B8): interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin’s lymphoma [abstract]. Blood 1997; 90: 510a

    Google Scholar 

  194. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20-monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90: 2188–95

    PubMed  CAS  Google Scholar 

  195. Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76–82

    Article  PubMed  CAS  Google Scholar 

  196. Sadoun A, Patri S, Delwail V, et al. Molecular remission after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1994; 13: 217–9

    PubMed  CAS  Google Scholar 

  197. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366–76

    PubMed  CAS  Google Scholar 

  198. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–58

    PubMed  CAS  Google Scholar 

  199. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996; 124: 311–5

    PubMed  CAS  Google Scholar 

  200. Khouri IF, Przepiorka D, van Besien K, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97: 466–73

    Article  PubMed  CAS  Google Scholar 

  201. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–63

    PubMed  CAS  Google Scholar 

  202. Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–24

    PubMed  CAS  Google Scholar 

  203. Itälä M, Pelliniemi T-T, Rajamäki A, et al. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant 1998; 19: 647–51

    Article  Google Scholar 

  204. Khouri IF, Keating MJ, Przepiorka D, et al. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): graft-versus-leukemia (GVL) without acute graft-versus-host disease (GVHD) [abstract]. Blood 1995; 86: 457a

    Google Scholar 

  205. Pavletic ZS, Bierman PJ, Vose JM, et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 1998; 9: 1023–6

    Article  PubMed  CAS  Google Scholar 

  206. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia 1998; 12: 1699–707

    Article  PubMed  CAS  Google Scholar 

  207. Buhmann R, Nolte A, Westhaus D, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates differenttypes of effector cells. Blood 1999; 93: 1992–2002

    PubMed  CAS  Google Scholar 

  208. Wierda WG, Cantwell MJ, Rassenti LZ, et al. CD 154 (CD40-ligand) gene immunization of chronic lymphocytic leukemia: a phase I study [abstract]. Blood 1998; 92: 489a

    Google Scholar 

  209. Rubin P, Bennett JM, Begg C, et al. The comparison of total body irradiation vs. chlorambucil and prednisone for remission induction of active chronic lymphocytic leukemia: an ECOG study. Part I: Total body irradiation-response and toxicity. Int J Radiat Oncol Biol Phys 1981; 7(12): 1623–32

    Article  PubMed  CAS  Google Scholar 

  210. De Rossi G, Biagini C, Lopez M, et al. Treatment by splenic irradiation in 22 chronic lymphocytic leukemia patients. Tumori 1982; 68: 511–4

    PubMed  Google Scholar 

  211. Kalil N, Cheson BD. Chronic lymphocytic leukemia. Oncologist 1999 4(5): 352–69

    PubMed  CAS  Google Scholar 

  212. Chisesi T, Capnist G, Dal Fior S. Splenic irradiation in chronic lymphocytic leukemia. Eur J Haematol 1991; 46: 202–4

    Article  PubMed  CAS  Google Scholar 

  213. Paule B, Brion N, Brion G. Remission of autoimmune hemolytic anemia associated with chronic lymphocytic leukemia following splenic irradiation. Nouv Rev Fr Hematol 1989; 31: 413–5

    PubMed  CAS  Google Scholar 

  214. Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 1992; 89: 374–7

    Article  PubMed  CAS  Google Scholar 

  215. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med 1988; 319: 902–7

    Article  Google Scholar 

  216. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81–6

    Article  PubMed  CAS  Google Scholar 

  217. Itälä M, Helenius H, Nikoskelainen J, et al. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol 1992; 48: 266–70

    Article  PubMed  Google Scholar 

  218. Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia: results of a crossover study. Haematologica 1996; 81: 121–6

    PubMed  CAS  Google Scholar 

  219. Byrd JC, Hargis JB, Kester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995; 49: 135–42

    Article  PubMed  CAS  Google Scholar 

  220. Mehta J, Powles R, Singhal S, et al. Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation. Leuk Lymphoma 1997; 26: 83–8

    Article  PubMed  CAS  Google Scholar 

  221. Südhoff T, Arning M, Schneider W. Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Leukemia 1997; 11: S38–41

    PubMed  Google Scholar 

  222. Vadhan-Raj S, Velasquez WS, Butler JJ, et al. Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor. Am J Hematol 1990; 33: 189–97

    Article  PubMed  CAS  Google Scholar 

  223. O’Brien S, Kantarjian H, Beran M, et al. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11: 1631–5

    Article  PubMed  Google Scholar 

  224. Rose E, Rai K, Revicki D, et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoietin alfa (EPO) [abstract]. Blood 1994; 84: 526a

    Google Scholar 

  225. Pangalis GA, Poziopoulos C, Angelopoulou MK, et al. Effective treatment of disease-related anemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 1995; 89: 627–9

    Article  PubMed  CAS  Google Scholar 

  226. Kjeldsberg CR, Marty J. Prolymphocytic transformation of chronic lymphocytic leukemia. Cancer 1981; 48: 2447–57

    Article  PubMed  CAS  Google Scholar 

  227. Sibbald R, Catovsky D. Complete remission in prolymphocytic leukaemia with the combination chemotherapy: CHOP. Br J Haematol 1979; 42: 488–90

    Article  PubMed  CAS  Google Scholar 

  228. Taylor HG, Butler WM, Rhoads J, et al. Prolymphocytic leukemia: treatment with combination chemotherapy to include doxorubicin. Cancer 1982; 49: 1524–9

    Article  PubMed  CAS  Google Scholar 

  229. Swift JF, Wold HG, Gandara DR, et al. Prolymphocytic leukemia: serial response to therapy. Cancer 1984; 54: 978–80

    Article  PubMed  CAS  Google Scholar 

  230. Smith OP, Mehta AB. Fludarabine monophosphate for prolymphocytic leukaemia [letter]. Lancet 1990; II: 820

    Article  Google Scholar 

  231. Kantarjian HM, Childs C, O’Brien S, et al. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med 1991; 90: 223–8

    PubMed  CAS  Google Scholar 

  232. Sporn JR. Sustained response of refractory prolymphocytic leukemia to fludarabine. Acta Haematol 1991; 85: 209–11

    Article  PubMed  CAS  Google Scholar 

  233. Saven A, Lee T, Schlutz M, et al. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. Blood 1997; 15: 37–43

    CAS  Google Scholar 

  234. El’Agnaf MR, Ennis KE, Morris TCM, et al. Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia. Br J Haematol 1986; 63: 93–104

    Article  PubMed  Google Scholar 

  235. Döhner H, Ho AD, Thaler J, et al. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst 1993; 85: 658–62

    Article  PubMed  Google Scholar 

  236. Collins RH, Pineiro LA, Agura ED, et al. Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 627–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute, Executive Plaza North, Room 741, Bethesda, Maryland, 20892, USA

    Nelson Kalil &  Bruce D. Cheson

Authors
  1. Nelson Kalil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce D. Cheson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce D. Cheson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kalil, N., Cheson, B.D. Management of Chronic Lymphocytic Leukaemia. Drugs Aging 16, 9–27 (2000). https://doi.org/10.2165/00002512-200016010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200016010-00002

Keywords

Search

Navigation